Literature DB >> 7915809

AIDS dementia complex and didanosine.

P Portegies, R H Enting, M D de Jong, S A Danner, P Reiss, J Goudsmit, J M Lange.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7915809     DOI： 10.1016/s0140-6736(94)92252-7

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  5 in total

1.  Risk of HIV dementia and opportunistic brain disease in AIDS and zidovudine therapy.

Authors:  T Baldeweg; J Catalan; B G Gazzard
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-07       Impact factor: 10.154

2.  Selective inhibition of syncytium-inducing and nonsyncytium-inducing HIV-1 variants in individuals receiving didanosine or zidovudine, respectively.

Authors:  A B van't Wout; L J Ran; M D de Jong; M Bakker; R van Leeuwen; D W Notermans; A E Loeliger; F de Wolf; S A Danner; P Reiss; C A Boucher; J M Lange; H Schuitemaker
Journal:  J Clin Invest       Date:  1997-11-01       Impact factor: 14.808

Review 3.  Review of antiretroviral therapy in the prevention of HIV-related AIDS dementia complex (ADC).

Authors:  P Portegies
Journal:  Drugs       Date:  1995       Impact factor: 9.546

Review 4.  Combination antiretroviral therapy. Back to the future.

Authors:  J Lange
Journal:  Drugs       Date:  1995       Impact factor: 9.546

5.  Study on didanosine concentrations in cerebrospinal fluid. Implications for the treatment and prevention of AIDS dementia complex.

Authors:  D M Burger; C L Kraayeveld; P L Meenhorst; J W Mulder; R M Hoetelmans; C H Koks; J H Beijnen
Journal:  Pharm World Sci       Date:  1995-11-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.